Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.
Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials.
Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.
This podcast is for you if:
- You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership
- You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness
- You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny
- You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources
What you will learn:
CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma.
Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.
New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.
Next Steps:
Visit the Website: https://smartbiotechscientist.com
Email us: hello@bruehlmann-consulting.com
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran - Part 2
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.
In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.
Topics covered:
- The strategic advantage of B2B commercialization in consumer care biotech (02:46)
- Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)
- Building a pilot facility and moving toward technology licensing for global reach (05:33)
- Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)
- Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)
- What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)
- Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)
- Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)
- The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)
Strategic insight:
Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.
Explore the full story and hear Tim’s advice for both founders and innovators.
If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:
- Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
- Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
Connect with Tim Corcoran:
LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/
Deep Blue Biotech: www.deepbluebiotech.com
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here